セッション詳細

[O1]Oral Presentations 1

2026年3月2日(月) 13:50 〜 15:20
神戸ポートピアホテル(南館1F「大輪田」)
【研究開発 I, III】【サポート機関と拠点の共同研究】
【R&D I, III】【Joint Research between Support Institutions and R&D centers】

[O1-01]ワクチンのオフターゲット効果とアジュバントの役割
Vaccine's off-target effects and the role of adjuvant

*Ken J ISHII1,2,3 (1. Div. Vaccine Science, The Institute of Medical Science, The University of Tokyo (Japan), 2. International Vaccine Design Center (VDesC), The Institute of Medical Science, The University of Tokyo (Japan), 3. UTOPIA, The University of Tokyo (Japan))
コメント()

[O1-02]COVID-19を対象とした多能性幹細胞由来の汎用性T細胞製剤の開発
Development of universal off-the-shelf T cell medicine produced from pluripotent stem cells for the treatment of COVID-19

*Hiroshi Kawamoto1 (1. Institute for Life and Medical Sciences, Kyoto University (Japan))
コメント()

[O1-03]Clinical Trials at UTOPIA

*Michiko Koga1,2, Hiroshi Yotsuyanagi2,3 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. IMSUT Hospital, the Institute of Medical Science, the University of Tokyo (Japan), 3. Japan Institute for Health Security (Japan))
コメント()

[O1-04E]光を利用したmRNAデリバリー
mRNA delivery utilizing light

*Takahiro Nomoto1 (1. Graduate School of Arts and Sciences, The University of Tokyo (Japan))
コメント()

[O1-05E]先端ゲノム、オミクス解析技術の現状と支援サポート
Current Status and Support Services for Advanced Genomic and Omics Analysis Technologies

*Akinori Kanai1, Yutaka Suzuki1 (1. Graduate School of Frontier Sciences, The University of Tokyo (Japan))
コメント()

[O1-06]若齢と高齢カニクイザルにおけるH5N1高病原性鳥インフルエンザウイルスに対するバロキサビルとオセルタミビルの効果
Efficacy of baloxavir marboxil and oseltamivir phosphate against H5N1 highly pathogenic avian influenza virus in young and old cynomolgus macaques

*Yasushi Itoh1, Maki Kiso2, Hirohito Ishigaki1, Kiyoko Iwatsuki-Horimoto2, Kenichi Otaki1, Mutsumi Ito2, Masaki Imai2, Yukihiro Matsukawa1, Ryuta Uraki2, Seiya Yamayoshi2, Yoshihiro Kawaoka2 (1. Department of Pathology, Shiga University of Medical Science (Japan), 2. The UTOPIA Center, The University of Tokyo (Japan))
コメント()

[O1-07]Establishment of a novel non-human primate model of infectious disease: Toward accelerating vaccine development

*Emiko Urano1, Yasuhiro Yasutomi1 (1. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan))
コメント()

[O1-08]鼻咽頭ぬぐい液からの単一細胞解析プラットフォームの確立
Establishment of a Single-Cell Analysis Platform Using Nasopharyngeal Swab Samples

*Akari Suzuki1, Junna Kawasaki2,3, Sho Miyamoto2,3, Tadaki Suzuki2,3, Syuji Yonekura4, Kohtaro Fujihashi5, Kazuhiko Yamamoto1 (1. Center for integrative medical science, RIKEN (Japan), 2. Department of Infectious Disease Pathobiology, Graduate School of Medicine, Chiba University (Japan), 3. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 4. Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University (Japan), 5. Department of Human Mucosal Vaccinology, Chiba University Hospital (Japan))
コメント()

[O1-09]マルチオミクス解析に基づくワクチン免疫応答持続性の理解
Understanding the Persistence of Vaccine-Induced Immunity Through Multi-Omics Profiling

*Masato Kubo1 (1. Kyoto university (Japan))
コメント()